COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir
COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir
复制标题
DOI：
10.1093/cid/ciaa587
复制
发表时间：
2020-10-15
影响因子：
11.8
通讯作者：
Pawlotsky, Jean-Michel
中科院分区：
文献类型：
--
作者：
Pawlotsky, Jean-Michel
2019年12月出现了一种新的肺炎疫情，称为2019冠状病毒病（COVID-19），由一种新发现的冠状病毒严重急性呼吸综合征冠状病毒（SARS-CoV-2）引起。没有治疗方法可用于治疗这种感染，这种感染已经在全世界造成超过31万人死亡。本观点总结了支持使用阿利泊韦治疗COVID-19的强有力的科学论据，阿利泊韦是环孢菌素A的非免疫抑制类似物，具有强效亲环蛋白抑制特性，已达到3期临床开发。它们包括许多冠状病毒（包括严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒）生命周期的强烈亲环蛋白依赖性，以及临床前数据显示，在各种冠状病毒感染模型（包括SARS-CoV-2）中，阿利泊利韦具有强大的抗病毒和细胞保护特性。应立即在患有或有严重SARS-CoV-2感染风险的患者中对阿利司匹韦进行病毒学和临床终点检测。
December 2019 saw the emergence of a new epidemic of pneumonia of varying severity, called coronavirus disease 2019 (COVID-19), caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV-2). No therapeutic option is available to treat this infection that has already killed > 310 000 people worldwide. This Viewpoint summarizes the strong scientific arguments supporting the use of alisporivir, a nonimmunosuppressive analogue of cyclosporine A with potent cyclophilin inhibition properties that has reached phase 3 clinical development, for the treatment of COVID-19. They include the strong cyclophilin dependency of the life cycle of many coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, and preclinical data showing strong antiviral and cytoprotective properties of alisporivir in various models of coronavirus infection, including SARS-CoV-2. Alisporivir should be tested without delay on both virological and clinical endpoints in patients with or at risk of severe forms of SARS-CoV-2 infection.